Top-Rated StocksTop-RatedNASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $15.39 -0.18 (-1.16%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Denali Therapeutics Stock (NASDAQ:DNLI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Denali Therapeutics alerts:Sign Up Key Stats Today's Range$15.20▼$15.7950-Day Range$13.22▼$15.5752-Week Range$10.57▼$33.33Volume1.21 million shsAverage Volume1.42 million shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$33.62Consensus RatingBuy Company Overview Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Read More Denali Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreDNLI MarketRank™: Denali Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 157th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.12, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Denali Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.21% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 1.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.84 Percentage of Shares Shorted10.21% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 1.18%, indicating that investor sentiment is decreasing. News and Social Media3.9 / 5News Sentiment1.04 News SentimentDenali Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Denali Therapeutics this week, compared to 6 articles on an average week.Search Interest8 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,520,799.00 in company stock.Percentage Held by Insiders12.50% of the stock of Denali Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Stock News HeadlinesDenali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 806 SharesAugust 15, 2025 | insidertrades.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.62 Average Target Price from BrokeragesAugust 26 at 2:21 AM | americanbankingnews.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)Morgan Stanley Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock PriceAugust 20, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for DNLI FY2029 EarningsAugust 17, 2025 | americanbankingnews.comWedbush Has Positive Estimate for DNLI FY2025 EarningsAugust 17, 2025 | americanbankingnews.comWilliam Blair Issues Positive Estimate for DNLI EarningsAugust 15, 2025 | americanbankingnews.comDenali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 12, 2025 | finanznachrichten.deSee More Headlines DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $20.38 on January 1st, 2025. Since then, DNLI shares have decreased by 23.9% and is now trading at $15.5150. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings results on Monday, August, 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.02. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Top institutional investors of Denali Therapeutics include Norges Bank (2.72%), Geode Capital Management LLC (2.18%), Alliancebernstein L.P. (2.15%) and Fisher Asset Management LLC (1.04%). Insiders that own company stock include Marc Tessier-Lavigne, Ryan J Watts, Alexander O Schuth, Carole Ho, Vicki L Sato, Steve E Krognes and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/11/2025Today8/26/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNLI CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees430Year Founded2015Price Target and Rating Average Price Target for Denali Therapeutics$33.62 High Price Target$45.00 Low Price Target$24.00 Potential Upside/Downside+115.1%Consensus RatingBuy Rating Score (0-4)3.12 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$422.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.79% Return on Assets-36.39% Debt Debt-to-Equity Ratio0.01 Current Ratio10.27 Quick Ratio10.27 Sales & Book Value Annual Sales$330.53 million Price / Sales6.91 Cash FlowN/A Price / Cash FlowN/A Book Value$8.53 per share Price / Book1.83Miscellaneous Outstanding Shares146,210,000Free Float127,936,000Market Cap$2.29 billion OptionableOptionable Beta1.36 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:DNLI) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.